Brought to you by 
Dynogen to go public in reverse merger with Apex; withdrawn
29 Jul 2021
Executive Summary
Private biotech Dynogen (GI and uro/gyn treatments) has agreed to merge with Apex Bioventures, a special purpose acquisition company, and take on its public status.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Includes Contract
- Reverse Acquisition
- Special Purpose Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dynogen to go public in reverse merger with Apex; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice